1 – 10 of 21
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Long-term follow-up of the randomized, prospective Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance (SCHEDULE) trial
(
- Contribution to journal › Article
-
Mark
The Effect of Everolimus Versus Calcineurin Inhibitors on Quality of Life 10–12 Years After Heart Transplantation : The Results of a Randomized Controlled Trial (SCHEDULE Trial)
(
- Contribution to journal › Article
-
Mark
Randomized Trial of Cholesterol Lowering With Evolocumab for Cardiac Allograft Vasculopathy in Heart Transplant Recipients
(
- Contribution to journal › Article
- 2022
-
Mark
Healthcare resource use of patients with transthyretin amyloid cardiomyopathy
(
- Contribution to journal › Article
-
Mark
Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries
(
- Contribution to journal › Article
- 2021
-
Mark
Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden
(
- Contribution to journal › Article
- 2020
-
Mark
Mild acute cellular rejection and development of cardiac allograft vasculopathy assessed by intravascular ultrasound and coronary angiography in heart transplant recipients—a SCHEDULE trial substudy
(
- Contribution to journal › Article
-
Mark
Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients : Long-term Follow-up From the Randomized SCHEDULE Study
(
- Contribution to journal › Article
-
Mark
Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients
(
- Contribution to journal › Article
-
Mark
Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients : Design of the randomized controlled EVOLVD trial
(
- Contribution to journal › Article